Publication | Closed Access

1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3

Viral Hepatitis+/− RibavirinAntiviral Drug DevelopmentAntiviral TherapyHepatitisVirologyNs5b InhibitorNs5a InhibitorAntiviral DrugMedicineAntiviral CompoundViral Immunity